Patents by Inventor Steven R. Magnuson

Steven R. Magnuson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Janus kinase inhibitor compounds and methods
    Patent number: 8486950
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: July 16, 2013
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Simon Charles Goodacre, Yingjie Lai, Jun Liang, Steven R. Magnuson, Kirk D. Robarge, Mark S. Stanley, Vickie Hsiao-Wei Tsui, Karen Williams, Birong Zhang, Aihe Zhou
  • IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20130096104
    Abstract: The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy, as an inhibitor of TYK2 kinase and conditions related, such as inflammatory illnesses, inflammatory bowel disease or psoriasis.
    Type: Application
    Filed: March 15, 2011
    Publication date: April 18, 2013
    Applicant: GENENTECH, INC.
    Inventors: Yingjie Lai, Jun Liang, Steven R. Magnuson, Kirk D. Robarge, Vickie H. Tsui, Birong Zhang, Aihe Zhou
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120264747
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 21, 2012
    Publication date: October 18, 2012
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Wendy Liu
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120225855
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 6, 2012
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Christopher Hurley, Jun Liang, Wendy Liu, Joseph P. Lyssikatos
  • AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20120202788
    Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.
    Type: Application
    Filed: September 14, 2011
    Publication date: August 9, 2012
    Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120190665
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: July 2, 2010
    Publication date: July 26, 2012
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark Zak, Aihe Zhou, Bing-Yan Zhu
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120022043
    Abstract: The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
    Type: Application
    Filed: May 2, 2011
    Publication date: January 26, 2012
    Applicant: Genentech, Inc.
    Inventors: Jeffrey Blaney, Paul A. Gibbons, Emily Hanan, Joseph P. Lyssikatos, Steven R. Magnuson, Richard Pastor, Thomas E. Rawson, Aihe Zhou, Bing-Yan Zhu
  • JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20100317643
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof
    Type: Application
    Filed: June 10, 2010
    Publication date: December 16, 2010
    Applicant: GENENTECH, INC.
    Inventors: SIMON CHARLES GOODACRE, YINGJIE LAI, JUN LIANG, STEVEN R. MAGNUSON, KIRK D. ROBARGE, MARK S. STANLEY, VICKIE HSIAO-WEI TSUI, KAREN WILLIAMS, BIRONG ZHANG, AIHE ZHOU
  • Triazolopyridine JAK Inhibitor Compounds and Methods
    Publication number: 20100048557
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 19, 2009
    Publication date: February 25, 2010
    Inventors: Bing-Yan ZHU, Michael SIU, Steven R. MAGNUSON, Richard PASTOR, He HAIYING, Xiao YISONG, Zheng JIFU, Xu XING, Zhao JUNPING
  • TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20100035875
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 19, 2009
    Publication date: February 11, 2010
    Inventors: Bing-Yan ZHU, Michael SIU, Steven R. MAGNUSON, Richard PASTOR, He HAIYING, Xiao YISONG, Zheng JIFU, Xu XING, Zhao JUNPING, Wendy LIU
  • 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders
    Patent number: 7109196
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: September 19, 2006
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Patent number: 6919371
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: July 19, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders
    Patent number: 6900205
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: May 31, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders
    Publication number: 20040209866
    Abstract: The invention relates generally to naphthyridine derivatives of the formula 1
    Type: Application
    Filed: April 28, 2004
    Publication date: October 21, 2004
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sideny X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-&ggr; binding agents
    Patent number: 6787651
    Abstract: Disclosed are substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing PPAR-&ggr; mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: September 7, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Andreas Stolle, Jacques P. Dumas, William Carley, Philip D. G. Coish, Steven R. Magnuson, Yamin Wang, Dhanapalan Nagarathnam, Derek B. Lowe, Ning Su, William H. Bullock, Ann-Marie Campbell, Ning Qi, Jeremy L. Baryza, James H. Cook
  • 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Publication number: 20040072828
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Application
    Filed: September 17, 2003
    Publication date: April 15, 2004
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
    Patent number: 6699860
    Abstract: This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: March 2, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, William H. Bullock, Steven R. Magnuson, Stephen J. O'Connor, Roger A. Smith, Quanrong Shen, Qingjie Liu, Ning Su, Emil J. Velthuisen, Ann-Marie Campbell, Paul P. Ehrlich
  • 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders
    Publication number: 20040014751
    Abstract: The invention relates generally to naphthyridine derivatives of the formula 1
    Type: Application
    Filed: September 23, 2002
    Publication date: January 22, 2004
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Patent number: 6660752
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: December 9, 2003
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
    Publication number: 20030087902
    Abstract: Disclosed are substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing PPAR-&ggr; mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis.
    Type: Application
    Filed: October 9, 2001
    Publication date: May 8, 2003
    Inventors: Andreas Stolle, Jacques P. Dumas, William Carley, Philip D.G. Coish, Steven R. Magnuson, Yamin Wang, Dhanapalan Nagarathnam, Derek B. Lowe, Ning Su, William H. Bullock, Ann-Marie Campbell, Ning Qi, Jeremy L. Baryza, James H. Cook